Cargando…

Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins

We believe this is the first study to investigate associations between blood metabolites and neocortical amyloid burden (NAB) in the search for a blood-based biomarker for Alzheimer's disease (AD). Further, we present the first multi-modal analysis of blood markers in this field. We used blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Voyle, N, Kim, M, Proitsi, P, Ashton, N J, Baird, A L, Bazenet, C, Hye, A, Westwood, S, Chung, R, Ward, M, Rabinovici, G D, Lovestone, S, Breen, G, Legido-Quigley, C, Dobson, R J B, Kiddle, S J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068879/
https://www.ncbi.nlm.nih.gov/pubmed/26812040
http://dx.doi.org/10.1038/tp.2015.205
_version_ 1782460858481246208
author Voyle, N
Kim, M
Proitsi, P
Ashton, N J
Baird, A L
Bazenet, C
Hye, A
Westwood, S
Chung, R
Ward, M
Rabinovici, G D
Lovestone, S
Breen, G
Legido-Quigley, C
Dobson, R J B
Kiddle, S J
author_facet Voyle, N
Kim, M
Proitsi, P
Ashton, N J
Baird, A L
Bazenet, C
Hye, A
Westwood, S
Chung, R
Ward, M
Rabinovici, G D
Lovestone, S
Breen, G
Legido-Quigley, C
Dobson, R J B
Kiddle, S J
author_sort Voyle, N
collection PubMed
description We believe this is the first study to investigate associations between blood metabolites and neocortical amyloid burden (NAB) in the search for a blood-based biomarker for Alzheimer's disease (AD). Further, we present the first multi-modal analysis of blood markers in this field. We used blood plasma samples from 91 subjects enrolled in the University of California, San Francisco Alzheimer's Disease Research Centre. Non-targeted metabolomic analysis was used to look for associations with NAB using both single and multiple metabolic feature models. Five metabolic features identified subjects with high NAB, with 72% accuracy. We were able to putatively identify four metabolites from this panel and improve the model further by adding fibrinogen gamma chain protein measures (accuracy=79%). One of the five metabolic features was studied in the Alzheimer's Disease Neuroimaging Initiative cohort, but results were inconclusive. If replicated in larger, independent studies, these metabolic features and proteins could form the basis of a blood test with potential for enrichment of amyloid pathology in anti-amyloid trials.
format Online
Article
Text
id pubmed-5068879
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50688792016-10-20 Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins Voyle, N Kim, M Proitsi, P Ashton, N J Baird, A L Bazenet, C Hye, A Westwood, S Chung, R Ward, M Rabinovici, G D Lovestone, S Breen, G Legido-Quigley, C Dobson, R J B Kiddle, S J Transl Psychiatry Original Article We believe this is the first study to investigate associations between blood metabolites and neocortical amyloid burden (NAB) in the search for a blood-based biomarker for Alzheimer's disease (AD). Further, we present the first multi-modal analysis of blood markers in this field. We used blood plasma samples from 91 subjects enrolled in the University of California, San Francisco Alzheimer's Disease Research Centre. Non-targeted metabolomic analysis was used to look for associations with NAB using both single and multiple metabolic feature models. Five metabolic features identified subjects with high NAB, with 72% accuracy. We were able to putatively identify four metabolites from this panel and improve the model further by adding fibrinogen gamma chain protein measures (accuracy=79%). One of the five metabolic features was studied in the Alzheimer's Disease Neuroimaging Initiative cohort, but results were inconclusive. If replicated in larger, independent studies, these metabolic features and proteins could form the basis of a blood test with potential for enrichment of amyloid pathology in anti-amyloid trials. Nature Publishing Group 2016-01 2016-01-26 /pmc/articles/PMC5068879/ /pubmed/26812040 http://dx.doi.org/10.1038/tp.2015.205 Text en Copyright © 2016 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Voyle, N
Kim, M
Proitsi, P
Ashton, N J
Baird, A L
Bazenet, C
Hye, A
Westwood, S
Chung, R
Ward, M
Rabinovici, G D
Lovestone, S
Breen, G
Legido-Quigley, C
Dobson, R J B
Kiddle, S J
Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins
title Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins
title_full Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins
title_fullStr Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins
title_full_unstemmed Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins
title_short Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins
title_sort blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068879/
https://www.ncbi.nlm.nih.gov/pubmed/26812040
http://dx.doi.org/10.1038/tp.2015.205
work_keys_str_mv AT voylen bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT kimm bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT proitsip bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT ashtonnj bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT bairdal bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT bazenetc bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT hyea bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT westwoods bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT chungr bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT wardm bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT rabinovicigd bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT lovestones bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT breeng bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT legidoquigleyc bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT dobsonrjb bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins
AT kiddlesj bloodmetabolitemarkersofneocorticalamyloidbburdendiscoveryandenrichmentusingcandidateproteins